Publications

Slifka MK, Hammarlund E, Lewis MW, Poore EA, Hanifin JM, Marr KA, Hecox D, Amanna IJ. Antiviral Immune Response After Live Yellow Fever Vaccination of a Kidney Transplant Recipient Treated With IVIG. Transplantation. 2013 May 15;95(9)

Pinto AK, Richner JM, Poore EA, Patil PP, Amanna IJ, Slifka MK, Diamond MS. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice. J Virol. 2013 Feb;87(4):1926-36.

Amanna IJ, Hammarlund E, Lewis MW, Slifka MK. Impact of infection or vaccination on pre-existing serological memory. Hum Immunol. 2012 Nov;73(11):1082-6.

Amanna IJ. Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longev Sci. 2012 Jun 29;6(2012):64-72.

Amanna IJ, Raué HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med. 2012 Jun;18(6):974-9.

Dubois ME, Hammarlund E, Slifka MK. Optimization of peptide-based ELISA for serological diagnostics: a retrospective study of human monkeypox infection. Vector Borne Zoonotic Dis. 2012 May;12(5):400-9.

Hammarlund E, Amanna IJ, Dubois ME, Barron A, Engelmann F, Messaoudi I, Slifka MK. A flow cytometry-based assay for quantifying non-plaque forming strains of yellow fever virus. PLoS One. 2012;7(9).

Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Frueh K. Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence. J Virol. 2011 Oct;85(19):10154-66.

Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology. 2011 Mar 15;411(2):206-15.

Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev. 2010 Jul;236:125-38.

Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res. 2009 Nov;84(2):119-30.

Dubois ME, Yoshihara P, Slifka MK. Antibody-mediated protection against respiratory viral infection. Semin Respir Crit Care Med. 2005 Dec;26(6):635-42.